{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T04:50:45Z","timestamp":1780548645711,"version":"3.54.1"},"reference-count":43,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2023.11997","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T12:06:44Z","timestamp":1683288404000},"source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of vedolizumab in the treatment of patients with inflammatory bowel disease: A systematic review and meta\u2011analysis of randomized controlled trials"],"prefix":"10.3892","volume":"25","author":[{"given":"Hui-Jun","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Shenzhen Integrated Traditional Chinese and Western Medicine Hospital, Shenzhen, Guangdong 518104, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai-Qun","family":"Bie","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shenzhen Integrated Traditional Chinese and Western Medicine Hospital, Shenzhen, Guangdong 518104, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Liangzi","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong 510632, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Xian","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong 510632, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Hui","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong 510632, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"key":"key20230526101748_b1-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"113","DOI":"10.25122\/jml-2018-0075","article-title":"A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease","volume":"12","author":"Seyedian","year":"2019","journal-title":"J Med Life"},{"key":"key20230526101748_b2-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68 (Suppl 3)","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"key20230526101748_b3-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.autrev.2019.03.002","article-title":"Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review","volume":"18","author":"Jeong","year":"2019","journal-title":"Autoimmun Rev"},{"key":"key20230526101748_b4-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/apt.14422","article-title":"Systematic review with network meta-analysis: First-and second-line pharmacotherapy for moderate-severe ulcerative colitis","volume":"47","author":"Singh","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"key20230526101748_b5-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","article-title":"An overview of the mechanism of action of the monoclonal antibody vedolizumab","volume":"10","author":"Wyant","year":"2016","journal-title":"J Crohns Colitis"},{"issue":"n71","key":"key20230526101748_b6-ETM-25-6-11997","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"d5928","key":"key20230526101748_b7-ETM-25-6-11997","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"243","key":"key20230526101748_b8-ETM-25-6-11997","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-017-0630-4","article-title":"Quantifying heterogeneity in individual participant data meta-analysis with binary outcomes","volume":"6","author":"Chen","year":"2017","journal-title":"Syst Rev"},{"key":"key20230526101748_b9-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.0006-341x.2000.00455.x","article-title":"Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis,'","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"key20230526101748_b10-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa042982","article-title":"Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin","volume":"352","author":"Feagan","year":"2005","journal-title":"N Engl J Med"},{"key":"key20230526101748_b11-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/ibd.21896","article-title":"Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose-ranging study","volume":"18","author":"Parikh","year":"2012","journal-title":"In\ufb02amm Bowel Dis"},{"key":"key20230526101748_b12-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"key20230526101748_b13-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.cgh.2016.08.044","article-title":"Ef\ufb01cacy of Vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists","volume":"15","author":"Feagan","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"e0212989","key":"key20230526101748_b14-ETM-25-6-11997","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212989","article-title":"Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study","volume":"14","author":"Motoya","year":"2019","journal-title":"PLoS One"},{"key":"key20230526101748_b15-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1053\/j.gastro.2019.08.027","article-title":"Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"key20230526101748_b16-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.cgh.2008.06.007","article-title":"Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin","volume":"6","author":"Feagan","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key20230526101748_b17-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"key20230526101748_b18-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"key":"key20230526101748_b19-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/MIB.0000000000000979","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease in patients na\u00efve to or who have failed tumor necrosis factor antagonist therapy","volume":"23","author":"Sands","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"key20230526101748_b20-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00535-019-01647-w","article-title":"Effects of vedolizumab in Japanese patients with Crohn's disease: A prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses","volume":"55","author":"Watanabe","year":"2020","journal-title":"J Gastroenterol"},{"key":"key20230526101748_b21-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/ecco-jcc\/jjab133","article-title":"Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn's disease: Results from the VISIBLE 2 Randomised trial","volume":"16","author":"Vermeire","year":"2022","journal-title":"J Crohns Colitis"},{"key":"key20230526101748_b22-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.chc.2010.01.007","article-title":"Inflammatory bowel disease","volume":"19","author":"Szigethy","year":"2010","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"key20230526101748_b23-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3748\/wjg.v20.i1.6","article-title":"Immunopathology of inflammatory bowel disease","volume":"20","author":"Wallace","year":"2014","journal-title":"World J Gastroenterol"},{"key":"key20230526101748_b24-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nrgastro.2012.152","article-title":"The gut microbiota in IBD","volume":"9","author":"Manichanh","year":"2012","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"key20230526101748_b25-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"3790","DOI":"10.3748\/wjg.v18.i29.3790","article-title":"Crucial steps in the natural history of inflammatory bowel disease","volume":"18","author":"Latella","year":"2012","journal-title":"World J Gastroenterol"},{"key":"key20230526101748_b26-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.3748\/wjg.v20.i12.3255","article-title":"Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease","volume":"20","author":"Xu","year":"2014","journal-title":"World J Gastroenterol"},{"key":"key20230526101748_b27-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1001\/jamapediatrics.2015.1982","article-title":"Inflammatory bowel disease in children and adolescents","volume":"169","author":"Rosen","year":"2015","journal-title":"JAMA Pediatr"},{"key":"key20230526101748_b28-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"key20230526101748_b29-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: Ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"key20230526101748_b30-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1159\/000233283","article-title":"Therapeutic options to modulate barrier defects in inflammatory bowel disease","volume":"27","author":"Hering","year":"2009","journal-title":"Dig Dis"},{"key":"key20230526101748_b31-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1586\/17512433.2016.1133288","article-title":"Optimization of anti-TNF therapy in patients with inflammatory bowel disease","volume":"9","author":"Strik","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"key20230526101748_b32-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nrgastro.2013.253","article-title":"Tailoring anti-TNF therapy in IBD: Drug levels and disease activity","volume":"11","author":"Ben-Horin","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"key20230526101748_b33-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: Loss of response to anti-TNF treatments in Crohn's disease","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"key20230526101748_b34-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2147\/CEG.S293272","article-title":"Anti-Integrins for the treatment of inflammatory bowel disease: Current evidence and perspectives","volume":"14","author":"Gubatan","year":"2021","journal-title":"Clin Exp Gastroenterol"},{"key":"key20230526101748_b35-ETM-25-6-11997","doi-asserted-by":"crossref","first-page":"11478","DOI":"10.1016\/S0021-9258(18)60831-2","article-title":"Characterization of the cell surface heterodimer VLA-4 and related peptides","volume":"262","author":"Hemler","year":"1987","journal-title":"J Biol Chem"},{"key":"key20230526101748_b36-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.2165\/00003495-200666090-00002","article-title":"Novel treatment options for inflammatory bowel disease: Targeting alpha 4 integrin","volume":"66","author":"Lanzarotto","year":"2006","journal-title":"Drugs"},{"key":"key20230526101748_b37-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1124\/jpet.109.153973","article-title":"The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases","volume":"330","author":"Soler","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"key20230526101748_b38-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.dld.2020.10.018","article-title":"Clinical guidelines for the management of inflammatory bowel disease: Update of a French national consensus","volume":"53","author":"Amiot","year":"2021","journal-title":"Dig Liver Dis"},{"key":"key20230526101748_b39-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review","volume":"142","author":"Molodecky","year":"2012","journal-title":"Gastroenterology"},{"key":"key20230526101748_b40-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1093\/ibd\/izz182","article-title":"Prevalence of inflammatory bowel disease in pediatric and adult populations: Recent estimates from large national databases in the United States,2007-2016","volume":"26","author":"Ye","year":"2020","journal-title":"Inflamm Bowel Dis"},{"issue":"e326","key":"key20230526101748_b41-ETM-25-6-11997","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000326","article-title":"PRISMA-efficacy and safety of vedolizumab for inflammatory bowel diseases: A systematic review and meta-analysis of randomized controlled trials","volume":"93","author":"Wang","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"key20230526101748_b42-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1007\/s00535-018-1480-0","article-title":"Systematic review with meta-analysis: Real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease","volume":"53","author":"Schreiber","year":"2018","journal-title":"J Gastroenterol"},{"key":"key20230526101748_b43-ETM-25-6-11997","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1097\/MIB.0000000000000396","article-title":"Vedolizumab for induction and maintenance of remission in ulcerative colitis: A Cochrane systematic review and meta-analysis","volume":"21","author":"Mosli","year":"2015","journal-title":"Inflamm Bowel Dis"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T10:21:12Z","timestamp":1685096472000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2023.11997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,5,5]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2023.11997","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,5]]},"article-number":"298"}}